NCT00002394

Brief Summary

The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

December 1, 1999

First QC Date

November 2, 1999

Last Update Submit

June 23, 2005

Conditions

Keywords

AIDS-Related Opportunistic InfectionsDose-Response Relationship, DrugFluconazoleAntifungal AgentsCandidiasis, OralDrug Administration Scheduleterbinafine

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • You may be eligible for this study if you:
  • Are at least 18 years old.
  • Have thrush that has not responded to at least 10 days of fluconazole treatment.
  • Are HIV-positive.
  • Are expected to live at least 4 weeks.
  • Are able to take oral medication.

You may not qualify if:

  • You will not be eligible for this study if you:
  • Have liver or kidney disease.
  • Have received certain medications.
  • Have a history of serious diarrhea or digestive problems.
  • Are pregnant or breast-feeding.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Therafirst Med Ctr

Fort Lauderdale, Florida, 33308, United States

Location

Associates in Research

Fort Myers, Florida, 33901, United States

Location

Clireco Inc

Tamarac, Florida, 33321, United States

Location

Infectious Diseases Research Inc

Tampa, Florida, 33614, United States

Location

Northwestern Univ / Division of Infectious Disease

Chicago, Illinois, 60611, United States

Location

Saint Michaels Med Ctr / Infectious Disease Resch Dpt

Newark, New Jersey, 071029880, United States

Location

St Vincents Hosp / Clinical Research Program

New York, New York, 10011, United States

Location

Univ of Texas Med Branch

Galveston, Texas, 77555, United States

Location

Hampton Roads Med Specialists

Hampton, Virginia, 23666, United States

Location

MeSH Terms

Conditions

Candidiasis, OralHIV InfectionsAIDS-Related Opportunistic Infections

Interventions

Terbinafine

Condition Hierarchy (Ancestors)

CandidiasisMycosesBacterial Infections and MycosesInfectionsMouth DiseasesStomatognathic DiseasesBlood-Borne InfectionsCommunicable DiseasesSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesOpportunistic Infections

Intervention Hierarchy (Ancestors)

NaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

June 24, 2005

Record last verified: 1999-12

Locations